植入式血流动力学监测改善射血分数降低心衰患者生存
该患者水平汇总荟萃分析纳入3项随机研究共1350例HFrEF患者,评估植入式血流动力学监测指导管理对全因死亡和心衰住院的影响。结果显示监测指导管理显著降低全因死亡(HR 0.75,95%CI 0.57-0.99,P=0.043)和心衰住院(HR 0.64,95%CI 0.55-0.76,P<0.0001)。
要点
- 植入式血流动力学监测指导管理可显著降低HFrEF患者全因死亡风险。
- 监测指导管理显著减少HFrEF患者心衰住院。
- 心衰住院下降见于监测第一年内,死亡获益在第一年后出现。
核心结论
- 对HFrEF患者采用植入式血流动力学监测指导管理可显著降低死亡率和心衰住院。
研究设计与样本
- 患者水平汇总荟萃分析纳入3项随机研究(GUIDE-HF、CHAMPION、LAPTOP-HF),共1350例HFrEF患者。
- 植入式监测器中2种测量肺动脉压力,1种测量左心房压力。
主要发现
- 血流动力学监测指导管理显著降低全因死亡,HR 0.75(95%CI 0.57-0.99),P=0.043。
- 心衰住院显著减少,HR 0.64(95%CI 0.55-0.76),P<0.0001。
- 心衰住院下降见于监测第一年内,死亡获益在第一年后出现。
临床怎么用
- 对HFrEF患者可考虑使用植入式血流动力学监测指导管理,以降低死亡和心衰住院风险。
局限性
- 既往评估死亡率的荟萃分析因缺乏患者水平数据、随访时间短及未覆盖全部射血分数谱而受限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Trials evaluating implantable hemodynamic monitors to manage patients with heart failure (HF) have shown reductions in HF hospitalizations but not mortality. Prior meta-analyses assessing mortality have been limited in construct because of an absence of patient-level data, short-term follow-up duration, and evaluation across the combined spectrum of ejection fractions. OBJECTIVES: The purpose of this meta-analysis was to determine whether management with implantable hemodynamic monitors reduces mortality in patients with heart failure and reduced ejection fraction (HFrEF) and to confirm the effect of hemodynamic-monitoring guided management on HF hospitalization reduction reported in previous studies. METHODS: The patient-level pooled meta-analysis used 3 randomized studies (GUIDE-HF [Hemodynamic-Guided Management of Heart Failure], CHAMPION [CardioMEMS Heart Sensor Allows Monitoring of Pressure to Improve Outcomes in NYHA Class III Heart Failure Patients], and LAPTOP-HF [Left Atrial Pressure Monitoring to Optimize Heart Failure Therapy]) of implantable hemodynamic monitors (2 measuring pulmonary artery pressures and 1 measuring left atrial pressure) to assess the effect on all-cause mortality and HF hospitalizations. RESULTS: A total of 1,350 patients with HFrEF were included. Hemodynamic-monitoring guided management significantly reduced overall mortality with an HR of 0.75 (95% CI: 0.57-0.99); P = 0.043. HF hospitalizations were significantly reduced with an HR of 0.64 (95% CI: 0.55-0.76); P < 0.0001. CONCLUSIONS: Management of patients with HFrEF using an implantable hemodynamic monitor significantly reduces both mortality and HF hospitalizations. The reduction in HF hospitalizations is seen early in the first year of monitoring and mortality benefits occur after the first year.
引用
- Lindenfeld, Costanzo, Zile, et al. Implantable Hemodynamic Monitors Improve Survival in Patients With Heart Failure and Reduced Ejection Fraction. J Am Coll Cardiol. 2024. PMID: 38325994. doi:10.1016/j.jacc.2023.11.030
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。